Wallace M/LinkedIn
Jan 3, 2026, 14:08
Wallace M Shares a SWOT Analysis of Aqvesme’s FDA Approval
Wallace M, CEO and Founder of i3consult.com, shared on LinkedIn:
”FDA APPROVAL UPDATE: Aqvesme™ (mitapivat) for Thalassemia‑Related Anemia
The FDA approval of Aqvesme™ introduces the first oral, disease‑modifying therapy for anemia in adults with alpha‑ or beta‑thalassemia.
Our latest SWOT analysis explores the clinical significance and strategic implications of this milestone.
Read the full analysis.”
Stay updated with Hemostasis Today.
-
Oct 4, 2026, 15:06Vasiliki Gkalea: Journal of Clinical Medicine Launches Special Issue on Hematologic Thrombosis and Bleeding
-
Oct 4, 2026, 14:55Quentin Brebant: What Defines a High-Quality Red Blood Cell Concentrate?
-
Oct 4, 2026, 14:47Rana Al-Hrout: Recognizing Non-Anemic Iron Deficiency – Why Iron Matters Beyond Hemoglobin
-
Oct 4, 2026, 14:41David McIntosh: International Plasma Awareness Week 2026 – Closing the Global Plasma Gap
-
Oct 4, 2026, 14:33Pete Stibbs: CleanerVac Real-World Study Presented at VIVA and The VEINS 2026
-
Oct 4, 2026, 13:56Maria Elisa Mancuso: EHC 2026 Highlights the Unmet Needs of Women with Bleeding Disorders
-
Oct 4, 2026, 13:53Nirmal Shaji George: Individualizing Anticoagulation in Complex APS and Thrombocytopenia
-
Oct 4, 2026, 13:5210 Posts Not to Miss This Week
-
Oct 4, 2026, 13:45Suswapna Singh Rawat: The Clinical Significance of Coronary Plaque Stability